Want to see JP:7459 full AI Analyst Report?
Top Page
Medipal Holdings
(7459)
Select Model
Select Model
Rating:72Outperform
Price Target:
¥3,139.00
▲(8.50% Upside)
Action:Upgraded
Date:08/17/26
The score is driven primarily by strong financial stability (very low leverage and steady revenue growth), tempered by thin margins and uneven cash flow. Technicals are neutral-to-mixed with modest momentum, and valuation is reasonable with a moderate P/E and a supportive dividend yield.
Positive Factors
Resilient Revenue Growth
Steady multi-year revenue growth indicates durable demand for pharmaceutical and healthcare distribution. The recurring replenishment needs of pharmacies, hospitals and clinics can support resilient volumes across economic cycles.
Negative Factors
Structurally Thin Margins
Wholesale distribution operates on limited spreads, leaving modest protection against procurement, logistics or labor-cost inflation. Thin margins also mean small changes in pricing, product mix or operating efficiency can materially affect earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Resilient Revenue Growth
Steady multi-year revenue growth indicates durable demand for pharmaceutical and healthcare distribution. The recurring replenishment needs of pharmacies, hospitals and clinics can support resilient volumes across economic cycles.
Read all positive factors
Medipal Holdings (7459) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥523.10B
Dividend Yield2.29%
Average Volume (3M)365.88K
Price to Earnings (P/E)12.7
Beta (1Y)0.33
Revenue Growth4.17%
EPS Growth15.59%
CountryJP
Employees13,024
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)227.17
Shares Outstanding215,975,040
10 Day Avg. Volume365,940
30 Day Avg. Volume365,883
Financial Highlights & Ratios
PEG Ratio2.04
Price to Book (P/B)0.93
Price to Sales (P/S)0.16
P/FCF Ratio15.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,900.00Price Target Upside0.24% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)213.13
Revenue Forecast (FY)¥3.94T
Medipal Holdings Business Overview & Revenue Model
Company Description
Medipal Holdings Corporation, a Tokyo, Japan-based company founded in 1898, primarily specializes in the wholesale distribution of prescription pharmaceuticals throughout Japan. The firm procures a broad spectrum of healthcare products, including ...
How the Company Makes Money
Medipal Holdings makes money primarily through wholesale distribution. Its main revenue model is selling products it procures from manufacturers (e.g., pharmaceutical makers and other healthcare suppliers) to healthcare providers and retail channe...
Medipal Holdings Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
86
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.86T | 3.82T | 3.67T | 3.56T | 3.36T | 3.29T |
| Gross Profit | 248.30B | 247.41B | 242.25B | 233.01B | 212.12B | 205.11B |
| EBITDA | 104.89B | 110.05B | 95.16B | 92.73B | 84.74B | 71.64B |
| Net Income | 46.59B | 42.53B | 40.28B | 41.48B | 38.81B | 29.42B |
Balance Sheet | ||||||
| Total Assets | 1.94T | 1.92T | 1.82T | 1.80T | 1.70T | 1.71T |
| Cash, Cash Equivalents and Short-Term Investments | 289.92B | 289.07B | 261.41B | 230.47B | 195.03B | 261.92B |
| Total Debt | 43.23B | 0.00 | 4.17B | 1.46B | 7.38B | 38.81B |
| Total Liabilities | 1.15T | 1.13T | 1.07T | 1.06T | 1.02T | 1.06T |
| Stockholders Equity | 649.73B | 652.17B | 619.57B | 600.35B | 561.36B | 530.30B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 39.93B | 51.70B | 46.28B | 5.66B | 45.26B |
| Operating Cash Flow | 0.00 | 46.55B | 60.56B | 61.84B | 16.15B | 61.22B |
| Investing Cash Flow | 0.00 | 9.30B | -3.36B | -7.82B | -39.47B | -24.34B |
| Financing Cash Flow | 0.00 | -29.40B | -25.95B | -25.25B | -43.56B | -16.47B |
Medipal Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥523.10B | 12.69 | 6.72% | 2.24% | 4.17% | 15.59% | |
71 Outperform | ¥293.59B | 9.53 | 9.37% | 1.91% | 4.65% | 23.21% | |
69 Neutral | ¥437.29B | 13.90 | 11.29% | 3.42% | 4.32% | 0.18% | |
69 Neutral | ¥513.38B | 15.60 | 10.75% | 1.20% | 12.20% | -25.42% | |
63 Neutral | ¥441.58B | 10.71 | 8.48% | 2.89% | 4.61% | 43.22% | |
54 Neutral | ¥401.20B | 23.67 | ― | 0.41% | 13.04% | -0.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7459
Medipal Holdings
2,883.50
301.97
11.70%
JP:2784
Alfresa Holdings
2,314.00
126.76
5.80%
JP:9989
Sundrug Co
3,740.00
-784.56
-17.34%
JP:7649
Sugi Holdings Co
1,321.00
-521.19
-28.29%
JP:9987
Suzuken Co
5,172.00
-690.56
-11.78%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,196.00
303.18
7.79%
Medipal Holdings Corporate Events
Medipal First-Quarter Profit Jumps as Dividend Plan Raised Despite Margin Pressure
Aug 5, 2026
Medipal Holdings reported first-quarter net sales of ¥989.5 billion, up 4.7% year on year, while operating profit slipped 4.7% and ordinary profit fell 1.7%. Profit attributable to owners of parent surged 42.3% to ¥13.6 billion, lifting ...
Medipal to Book ¥42.1 Billion in Subsidiary Dividends With No Impact on Consolidated Earnings
Jul 14, 2026
Medipal Holdings said it will receive a total of ¥42.1 billion in dividends from eight consolidated subsidiaries, with the payments scheduled to be received on July 15, 2026. The dividend income will be booked as operating income in the paren...
Medipal Raises Dividend Forecast on Earnings Boost From Paltac Acquisition
Jul 14, 2026
Medipal Holdings Corporation, listed on the Tokyo Stock Exchange Prime Market, operates in the pharmaceutical and healthcare-related distribution industry and is pursuing growth through consolidation of group companies. Its recent move to fully ac...
Medipal Lifts Net Profit Outlook After Paltac Takeover, Trims Operating Guidance
Jul 14, 2026
Medipal Holdings has revised its full-year consolidated forecast for the fiscal year ending March 31, 2027, keeping net sales unchanged at ¥3,944 billion but trimming operating and ordinary profit expectations due to expenses linked to a rece...
Medipal Completes Tender Offer to Boost Stake in Distributor Paltac
Jul 8, 2026
Medipal Holdings has announced the completion of its tender offer for common shares of Paltac Corporation, a TSE Prime Market-listed distributor, which ran from May 12 to July 7, 2026. The offer price was set at 6,650 yen per share, with a minimum...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.